Skip to main content
  • Login
  • Contact
  • Subscribe
  • Advertise With Us

Search form

Home

The Pilot News

Plymouth weather info

  • Home
    • Forms
  • News
    • Local News
    • The Leader of Starke County
    • Culver Citizen
    • Business News
  • Sports
  • Obituaries
  • Classifieds
    • Place an Ad
    • Classified Display Ads
  • Entertainment
    • Calendar
    • Best Of
    • Special Sections
    • Talking About...
    • Games
  • Photos
  • Videos
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Axsome Thera (NQ: AXSM)
92.59 USD  +0.44 (+0.48%)
Official Closing Price  /  Updated: 5:55 PM EST, Feb 20, 2020  /  Add to My Watchlist      
View: Quote
Overview
Detailed Quote
Charting
Historical Prices
 News
All News
Press Releases
Related Stories
Blogs
 Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 599,400
Open 92.22
Bid (Size) 91.02 (2)
Ask (Size) 92.99 (5)
Prev. Close 92.15
Today's Range 89.25 - 93.65
52wk Range 7.640 - 109.94
Shares Outstanding 25,685,492
Dividend Yield N/A
Performance
YTD
-8.61%
-8.61%
1 Month
+4.35%
+4.35%
3 Month
+171.37%
+171.37%
6 Month
+266.98%
+266.98%
1 Year
+954.56%
+954.56%
Top News
More News
Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine
Today 7:00 EST
from GlobeNewswire News Releases
Axsome Therapeutics to Present at Upcoming Investor Conferences
February 19, 2020
from GlobeNewswire News Releases
More News
Read More
Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
January 22, 2020
from GlobeNewswire News Releases
Global Brain Tumor Drugs Market Expected To Exceed $3 Billion Through 2022
January 14, 2020
category Featured News
from FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Brain Tumor Drugs Market Expected to Exceed $3 Billion Through 2022
January 14, 2020
from PR Newswire
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
January 13, 2020
from GlobeNewswire News Releases
Noteworthy Thursday Option Activity: AXSM, IDCC, INST
February 13, 2020
category Stocks
from Market News Video
DWAS's Underlying Holdings Could Mean 11% Gain Potential
January 23, 2020
category ETFs
from ETF Channel
6 Healthcare Stocks That Could Make You Filthy Rich
February 17, 2020
category PBYI , NVAX , ALPMF , and 6 more.
from Motley Fool
Are Biotech Stocks Due for a Correction in 2020?
January 15, 2020
category AXSM , SGEN , Market News , and 3 more.
from Motley Fool
Thinking about buying stock in Apple, Axsome Therapeutics, Crocs, Lululemon Athletica, or Tilray?
January 13, 2020
from PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2019 The Pilot News | 214 N. Michigan | Plymouth, IN 46563 | (574) 936-3101 • 800-933-0356
All property rights for the entire contents of this publication shall be the property of The Pilot News.
No part hereof may be reproduced without prior written consent.
Privacy and Terms of Use


Site Design, Programming & Development by Surf New Media